Advancement of AbbVie Inc. and OSE Immunotherapeutics strategic partnership to develop ABBV-230: in April 2024, the Hart-Scott-Rodino waiting period expired enabling teams to commence work around the ...

Since exploring some of the details about how the next Archbishop of Canterbury will be chosen, there have been a number of ...

Unlike monogenic (Mendelian) disorders or infectious disease, where the known primary cause permits an aetiological classification and rational approach to management, common diseases are generally ...

Background: Statins are generally well tolerated, but some patients discontinue therapy secondary to adverse effects. Dosing a statin (rosuvastatin) every other day (EOD) may provide significant ...